Kirkland & Ellis Represents China Traditional Chinese Medicine in its US$1.34 billion Acquisition of 81.48% of Jiangyin Tianjiang Pharmaceutical

Kirkland & Ellis is acting for Hong Kong-listed China Traditional Chinese Medicine Co. Limited (HKSE: 570) in its proposed US$1.34 billion acquisition of a 81.48% stake in Jiangyin Tianjiang Pharmaceutical Co. Ltd., the largest manufacturer of concentrated traditional Chinese medicine granules in China, from seven sellers including, among others, two CICC-affiliated funds, Shanghai-listed Shanghai Jiahua United Co., Ltd. (SSE: 600315) and Shanghai-listed Guangdong Keda Clean Energy Co., Ltd. (SSE: 600499).

The Kirkland team is led by Hong Kong-based corporate partner Frank Sun, and includes corporate partners David Yun and Joey Chau, corporate associate Anthony Chan and foreign legal consultant Yanyan Cai.

More information on the transaction is available here.

Kirkland has previously advised China Traditional Chinese Medicine (formerly known as “Winteam Pharmaceutical Group Limited”) on its US$430 million acquisition of the entire issued share capital of Tongjitang Chinese Medicine Company from Hanmax Investment Limited and Fosun Industrial Co., Limited, which closed in October 2013, and its three related equity financing transactions with an aggregate total of US$167 million.